Natco Pharma Limited has announced the Canadian launch of PrNAT-LENALIDOMIDE Capsules, a generic version of Celgene Corporation’s cancer drug Revlimid.

The launch was announced earlier this month by the Indian pharma company’s Canadian subsidiary — Natco Pharma (Canada).

PrNAT-LENADLIDOMIDE in combination with dexamethasone is approved by Health Canada for the treatment of multiple myeloma in patients who cannot undergo stem cell transplant.

Besides, PrNAT-LENALIDOMIDE is indicated for the treatment of transfusion-dependent anemia caused by low – or intermediate-1-risk myelodysplastic syndromes resulting from the deletion of 5q cytogenetic abnormality with or without other cytogenetic abnormalities.

Glenn Ikeda — CEO of Natco Pharma (Canada) said: “We are proud to have led the way for an accessible treatment option for multiple myeloma that may alleviate the financial burden for myeloma patients, as well as public and private payers.

“Our team has been working diligently to improve the supply of accessible, high-quality medicines to Canadian patients. The launch of PrNAT-LENALIDOMIDE represents an important milestone in Natco’s continued efforts to expand its product portfolio and is the result of considerable Canadian investment that will bring cost savings to healthcare at a critical time.”

According to Natco Pharma, rNAT-LENALIDOMIDE Capsules can be availed via the RevAid risk management plan in strengths of 2.5 mg, 5 mg, 10 mg, 15 mg, 20 mg and 25 mg capsules.

  Canada, cancer, Celgene, Dexamethasone, Glenn Ikeda, Health Canada, Multiple myeloma, Natco Pharma, Natco Pharma (Canada), Oncology, PrNAT-LENALIDOMIDE Capsules, REVLIMID